The Summary
Researchers conducted a national cohort study in Sweden involving over 95,000 individuals with depression or anxiety who used antidiabetic medications between 2009 and 2022. By comparing periods when individuals took GLP-1 receptor agonists to periods when they did not, scientists tracked rates of psychiatric hospitalization, self-harm, and severe sick leave. The study found that semaglutide and liraglutide were significantly associated with a lower risk of worsening mental illness. Specifically, semaglutide reduced the risk of worsening depression, anxiety, and substance use disorders, while GLP-1 medications as a group lowered the risk of self-harm.
Why this is interesting
Previous reports raised concerns that some modern diabetes medications might worsen mental health, leading to mixed warnings. This study turns that assumption on its head, suggesting that drugs like semaglutide might actually protect against severe mental health dips, including self-harm and anxiety, in people who already struggle with these conditions. For readers managing both metabolic and mental health conditions, this offers reassuring evidence that these medications are safe for psychiatric well-being and might even act as a dual treatment. However, more randomized clinical trials are still needed to confirm these exciting benefits.